The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement
Open accessAbstract
Mesenchymal stromal cells (MSCs) have been widely investigated for their therapeutic potential in regenerative medicine, owing to their ability to home damaged tissue and serve as a reservoir of growth factors and regenerative molecules. As such, clinical applications of MSCs are reliant on these cells successfully migrating to the desired tissue following their administration. Unfortunately, MSC homing is inefficient, with only a small percentage of cells reaching the target tissue following systemic administration. This attrition represents a major bottleneck in realizing the full therapeutic potential of MSC-based therapies. Accordingly, a variety of strategies have been employed in the hope of improving this process. Here, we review the molecular mechanisms underlying MSC homing, based on a multistep model involving (1) initial tethering by selectins, (2) activation by cytokines, (3) arrest by integrins, (4) diapedesis or transmigration using matrix remodelers, and (5) extravascular migration toward chemokine gradients. We then review the various strategies that have been investigated for improving MSC homing, including genetic modification, cell surface engineering, in vitro priming of MSCs, and in particular, ultrasound techniques, which have recently gained significant interest. Contextualizing these strategies within the multistep homing model emphasizes that our ability to optimize this process hinges on our understanding of its molecular mechanisms. Moving forward, it is only with a combined effort of basic biology and translational work that the potential of MSC-based therapies can be realized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
A perivascular origin for mesenchymal stem cells in multiple human organs
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.003 · Cited by 3,991
Frenette, P. S., Pinho, S., Lucas, D., & Scheiermann, C. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095919 · Cited by 462 · cited 1×
“Accordingly, MSCs have been investigated for a wide breadth of clinical applications, such as immune modulation in inflammatory and autoimmune diseases, tissue protection following injury, and regenerative medicine (Frenette et al., 2013).”
BackgroundInfluentialStromal cell-derived factor-1α is cardioprotective after myocardial infarction
Saxena, A., Fish, J. E., White, M. D., Yu, S., Smyth, J. W. P., Shaw, R. M., DiMaio, J. M., & Srivastava, D. (2008) · Circulation · doi:10.1161/circulationaha.107.694992 · Cited by 237
Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke
Vu, Q., Xie, K., Eckert, M., Zhao, W., & Cramer, S. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000278 · Cited by 235
Cited by
Shattering barriers toward clinically meaningful MSC therapies
Levy, O., Kuai, R., Siren, E. M. J., Bhere, D., Milton, Y., Nissar, N., De Biasio, M., Heinelt, M., Reeve, B., Abdi, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba6884 · Cited by 694
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01855-9 · Cited by 343
Alvites, R., Branquinho, M., Sousa, A. C., Lopes, B., Sousa, P., & Maurício, A. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020381 · Cited by 174
García-Bernal, D., García-Arranz, M., Yáñez, R. M., Hervás-Salcedo, R., Cortés, A., Fernández-García, M., Hernando-Rodríguez, M., Quintana-Bustamante, Ó., Bueren, J. A., García-Olmo, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650664 · Cited by 138
Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin
Qin, L., Liu, N., Bao, C.-L.-M., Yang, D.-Z., Ma, G.-X., Yi, W.-H., Xiao, G.-Z., & Cao, H.-L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00952-0 · Cited by 114
Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease
Yuan, M., Hu, X., Yao, L., Jiang, Y., & Li, L. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02858-4 · Cited by 89
Different sourced extracellular vesicles and their potential applications in clinical treatments
Bahmani, L., & Ullah, M. (2022) · Cells · doi:10.3390/cells11131989 · Cited by 83
Self-citationExosomes and Biomaterials: In Search of a New Therapeutic Strategy for Multiple Sclerosis
Ojeda-Hernández, D. D., Hernández-Sapiéns, M. A., Reza-Zaldívar, E. E., Canales-Aguirre, A., Matías-Guiu, J. A., Matías-Guiu, J., Mateos-Díaz, J. C., Gómez-Pinedo, U., & Sancho-Bielsa, F. (2022) · Life · doi:10.3390/life12091417 · Cited by 25
Controversies regarding transplantation of mesenchymal stem cells
Velikova, T., Dekova, T., & Miteva, D. G. (2024) · World Journal of Transplantation · doi:10.5500/wjt.v14.i2.90554 · Cited by 12
Teymouri, S., Yousefi, M. H., Heidari, S., Farokhi, S., Afkhami, H., & Kashfi, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-024-10163-x · Cited by 11
He, L., Xu, J., Huang, P., Bai, Y., Chen, H., Xu, X., Hu, Y., Liu, J., & Zhang, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137235 · Cited by 8
Metadata
- Authors
- Ullah, M., Liu, D. D., & Thakor, A. S.
- Venue
- iScience
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 15
- Pages
- 421-438
- ISSN
- 2589-0042 (ISSN-L)
- OpenAlex
- W2944196444
- Cited by
- 549
- References
- 5
- FWCI
- 29.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
